Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma.

PubWeight™: 1.53‹?› | Rank: Top 4%

🔗 View Article (PMID 17925550)

Published in J Clin Oncol on October 10, 2007

Authors

Daniëlle A M Heideman1, Tim Waterboer, Michael Pawlita, Pien Delis-van Diemen, Ingo Nindl, Joost A Leijte, Johannes M G Bonfrer, Simon Horenblas, Chris J L M Meijer, Peter J F Snijders

Author Affiliations

1: Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. dam.heideman@vumc.nl

Associated clinical trials:

Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen) (CaboPen) | NCT03943602

Articles citing this

Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87

Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14

Penile cancer: current therapy and future directions. Ann Oncol (2013) 1.54

Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer (2008) 1.48

Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ (2015) 1.43

Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol (2013) 1.34

Genital HPV infection and related lesions in men. Prev Med (2011) 1.19

An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer (2009) 1.14

InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J Natl Cancer Inst (2012) 1.09

Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res (2011) 1.05

Primary prevention and vaccination for penile cancer. Ther Adv Urol (2013) 0.99

Human papillomavirus is not associated with colorectal cancer in a large international study. Cancer Causes Control (2010) 0.98

Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study. J Clin Oncol (2015) 0.91

Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review. J Adolesc Health (2012) 0.89

Cutaneous human papillomavirus types detected on the surface of male external genital lesions: a case series within the HPV Infection in Men Study. J Clin Virol (2013) 0.88

Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study. Eur Urol (2015) 0.88

Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. Oncologist (2015) 0.88

Awareness and knowledge of human papillomavirus (HPV) infection among high-risk men of Hispanic origin attending a sexually transmitted infection (STI) clinic. BMC Infect Dis (2012) 0.86

Natural history of cutaneous human papillomavirus (HPV) infection in men: the HIM study. PLoS One (2014) 0.86

Histological characteristics of human papilloma-virus-positive and -negative invasive and in situ squamous cell tumours of the penis. Int J Exp Pathol (2009) 0.86

Human papillomavirus 18 E6 inhibits phosphorylation of p53 expressed in HeLa cells. Cell Biosci (2012) 0.85

The etiologic role of human papillomavirus in penile cancers: a study in Vietnam. Br J Cancer (2013) 0.85

Molecular prognostic factors in penile cancer. World J Urol (2008) 0.85

Buried penis: An unrecognized risk factor in the development of invasive penile cancer. Can Urol Assoc J (2012) 0.85

Human papillomavirus tumor infection in esophageal squamous cell carcinoma. J Gastrointest Oncol (2015) 0.84

Prevalence of human papillomavirus in penile malignant tumors: viral genotyping and clinical aspects. BMC Urol (2015) 0.84

High genital prevalence of cutaneous human papillomavirus DNA on male genital skin: the HPV Infection in Men Study. BMC Infect Dis (2014) 0.82

HPV frequency in penile carcinoma of Mexican patients: important contribution of HPV16 European variant. Int J Clin Exp Pathol (2013) 0.80

Diversity of human papillomavirus in the anal canal of men: the HIM Study. Clin Microbiol Infect (2015) 0.80

Detection of Human Papillomavirus DNA in Patients with Breast Tumor in China. PLoS One (2015) 0.79

Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma. Virol J (2013) 0.77

Seroprevalence of Cutaneous Human Papillomaviruses and the Risk of External Genital Lesions in Men: A Nested Case-Control Study. PLoS One (2016) 0.75

Genetic variants of a BH3-only pro-apoptotic gene, PUMA, and risk of HPV16-associated squamous cell carcinoma of the head and neck. Mol Carcinog (2011) 0.75

Cervical Infection with Cutaneous Beta and Mucosal Alpha Papillomaviruses. Cancer Epidemiol Biomarkers Prev (2017) 0.75

The economic burden of human papillomavirus-related precancers and cancers in Sweden. PLoS One (2017) 0.75

Comparison of the natural history of genital HPV infection among men by country: Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev (2017) 0.75

Articles by these authors

Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67

Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39

WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14

Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80

Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99

Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28

Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87

GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer (2011) 5.43

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol (2006) 5.20

Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet (2002) 5.00

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82

A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29

Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14

Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96

Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst (2004) 3.67

Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64

Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol (2011) 3.58

Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38

Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine (2006) 3.15

Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol (2006) 3.13

Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ (2002) 3.09

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine (2012) 3.09

EAU penile cancer guidelines 2009. Eur Urol (2010) 3.03

Suppression of non-specific binding in serological Luminex assays. J Immunol Methods (2005) 2.96

POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89

Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87

Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood (2007) 2.82

Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder. Int J Urol (2012) 2.76

Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst (2002) 2.75

Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol (2007) 2.68

Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol (2011) 2.52

Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. Eur Urol (2007) 2.44

Identification of high risk pathological node positive penile carcinoma: value of preoperative computerized tomography imaging. J Urol (2011) 2.42

Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst (2006) 2.40

Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis (2005) 2.20

Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol (2006) 2.20

Anatomical mapping of lymphatic drainage in penile carcinoma with SPECT-CT: implications for the extent of inguinal lymph node dissection. Eur Urol (2008) 2.19

Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15

Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients? J Urol (2012) 2.14

HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ (2010) 2.10

The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis (2005) 2.07

Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. BJU Int (2013) 2.06

The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol (2003) 2.04

HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol (2006) 2.03

Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol (2008) 2.02

Helicobacter pylori protein-specific antibodies and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2013) 2.01

Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol (2008) 2.00

Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control (2003) 2.00

Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer (2002) 1.98

HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods (2002) 1.97

Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol (2003) 1.96

Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol (2007) 1.95

Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol (2005) 1.94

Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis (2003) 1.93

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol (2011) 1.93

Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia (2004) 1.92

Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol (2008) 1.90

The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res (2009) 1.87

Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev (2010) 1.85

Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol (2010) 1.78

Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol (2008) 1.78

Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev (2006) 1.77

Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study. Int J Cancer (2003) 1.77

Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res (2012) 1.76

Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer (2003) 1.74

Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses. Int J Epidemiol (2004) 1.73

Inguinal recurrence following therapeutic lymphadenectomy for node positive penile carcinoma: outcome and implications for management. J Urol (2011) 1.72

High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer (2012) 1.71

Human papillomavirus infection among women in South and North Vietnam. Int J Cancer (2003) 1.71

Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. Eur Urol (2009) 1.71